Anti-CCP

Anti-Cyclic Citrullinated Peptide Antibodies

Q: What is the difference between anti-CCP and rheumatoid factor?

Both are autoantibodies associated with RA, but they differ in specificity and clinical utility. Rheumatoid factor (RF) is an antibody against the Fc portion of IgG and is present in about 70–80% of RA patients, but it also appears in many other conditions (infections, other autoimmune diseases, and even in 5–10% of healthy individuals). Anti-CCP is 95–98% specific for RA, making a positive result much more diagnostic. Using both tests together provides the highest diagnostic accuracy. Double-positive (RF+ and anti-CCP+) patients have the most aggressive disease.

Q: Can anti-CCP predict how severe my RA will be?

Yes, anti-CCP positivity is one of the strongest predictors of erosive, progressive RA. Patients who are anti-CCP positive tend to develop more radiographic joint damage over time compared to those who are anti-CCP negative. Higher titers of anti-CCP are associated with worse outcomes. This prognostic information is used to make treatment decisions—anti-CCP-positive patients may be started on more aggressive therapy earlier to prevent joint destruction.

Q: Can anti-CCP antibodies go away?

Anti-CCP antibodies rarely convert from positive to negative, even with successful treatment. They reflect an established immune response to citrullinated proteins. While effective therapy can achieve disease remission and normalize inflammatory markers like CRP, anti-CCP titers typically remain elevated. The persistence of anti-CCP antibodies is one reason why RA is considered a chronic disease requiring ongoing management, even when symptoms are well controlled.

Immune & Inflammation

What is Anti-Cyclic Citrullinated Peptide Antibodies?

Anti-cyclic citrullinated peptide (anti-CCP) antibodies, also known as anti-citrullinated protein antibodies (ACPA), are autoantibodies directed against proteins that have undergone citrullination—a post-translational modification in which the amino acid arginine is converted to citrulline by peptidylarginine deiminase (PAD) enzymes. This modification can occur in many proteins including fibrinogen, vimentin, alpha-enolase, and type II collagen. In genetically susceptible individuals (particularly those carrying HLA-DRB1 shared epitope alleles), the immune system mounts a response against these citrullinated proteins, producing anti-CCP antibodies that are highly specific for rheumatoid arthritis (RA).

Anti-CCP testing has revolutionized the diagnosis of rheumatoid arthritis. The second-generation anti-CCP2 assay (the most widely used) has a specificity of 95–98% for RA, meaning a positive result is highly predictive of the disease. Anti-CCP antibodies can be detected years before the onset of clinical symptoms—up to 10 years before joint inflammation appears—making them valuable for early diagnosis. They are also a powerful prognostic marker: anti-CCP-positive RA tends to be more aggressive, with greater radiographic joint damage and erosions compared to anti-CCP-negative disease.

Why It Matters

Anti-CCP has transformed early RA diagnosis and management. Its high specificity (95–98%) makes it far more reliable than rheumatoid factor (RF) alone, which is positive in only about 70% of RA patients and can be elevated in many other conditions. The combination of anti-CCP and RF positivity confers the highest diagnostic certainty for RA. Critically, anti-CCP positivity identifies patients at risk for more aggressive, erosive disease, enabling earlier initiation of disease-modifying antirheumatic drugs (DMARDs) before irreversible joint destruction occurs. This "window of opportunity" in early RA—where aggressive treatment can alter the disease course—makes timely anti-CCP testing clinically impactful.

Normal Reference Ranges

Group	Range	Unit
Negative	<20	U/mL
Weak positive	20–39	U/mL
Moderate positive	40–59	U/mL
Strong positive	≥60	U/mL

Reference ranges may vary by laboratory. Always compare results to the ranges provided by your testing facility.

What High Anti-CCP Levels Mean

Common Causes

Rheumatoid arthritis (present in 60–80% of RA patients)
Pre-clinical rheumatoid arthritis (detectable years before symptoms)
Rarely positive in other conditions: psoriatic arthritis, SLE, Sjogren's syndrome, tuberculosis
Smoking increases risk of developing anti-CCP antibodies in genetically susceptible individuals

Possible Symptoms

Anti-CCP itself does not cause symptoms
Symmetric joint pain and swelling, particularly in small joints of hands and feet
Morning stiffness lasting more than 30 minutes
Fatigue
Joint tenderness and warmth
Rheumatoid nodules (firm bumps under the skin)

What to do: A positive anti-CCP in a patient with inflammatory joint symptoms strongly supports a diagnosis of RA. Rheumatology referral should be arranged promptly, ideally within 6 weeks of symptom onset. Additional workup includes rheumatoid factor, CRP, ESR, X-rays of hands and feet, and possibly musculoskeletal ultrasound or MRI. Early initiation of DMARDs (methotrexate is first-line) within the "window of opportunity" can prevent erosive disease and improve long-term outcomes. Even if symptoms are minimal, a positive anti-CCP warrants close monitoring.

What Low Anti-CCP Levels Mean

Common Causes

Negative anti-CCP is the normal result
Seronegative rheumatoid arthritis (20–40% of RA patients are anti-CCP negative)

Possible Symptoms

No symptoms from a negative anti-CCP

What to do: A negative anti-CCP does not exclude RA—approximately 20–40% of RA patients are "seronegative." If clinical suspicion for RA remains high, the diagnosis can be made based on clinical criteria, imaging findings, and other labs. Seronegative RA generally has a somewhat better prognosis with less erosive disease, but still requires treatment with DMARDs. Musculoskeletal ultrasound can detect subclinical synovitis in seronegative patients.

When Is Anti-CCP Testing Recommended?

When rheumatoid arthritis is suspected (symmetric inflammatory polyarthritis, prolonged morning stiffness)
In conjunction with rheumatoid factor for RA diagnosis
When differentiating RA from other forms of arthritis
In patients with undifferentiated inflammatory arthritis to assess RA risk
In first-degree relatives of RA patients with early joint symptoms

Frequently Asked Questions

Both are autoantibodies associated with RA, but they differ in specificity and clinical utility. Rheumatoid factor (RF) is an antibody against the Fc portion of IgG and is present in about 70–80% of RA patients, but it also appears in many other conditions (infections, other autoimmune diseases, and even in 5–10% of healthy individuals). Anti-CCP is 95–98% specific for RA, making a positive result much more diagnostic. Using both tests together provides the highest diagnostic accuracy. Double-positive (RF+ and anti-CCP+) patients have the most aggressive disease.

Yes, anti-CCP positivity is one of the strongest predictors of erosive, progressive RA. Patients who are anti-CCP positive tend to develop more radiographic joint damage over time compared to those who are anti-CCP negative. Higher titers of anti-CCP are associated with worse outcomes. This prognostic information is used to make treatment decisions—anti-CCP-positive patients may be started on more aggressive therapy earlier to prevent joint destruction.

Anti-CCP antibodies rarely convert from positive to negative, even with successful treatment. They reflect an established immune response to citrullinated proteins. While effective therapy can achieve disease remission and normalize inflammatory markers like CRP, anti-CCP titers typically remain elevated. The persistence of anti-CCP antibodies is one reason why RA is considered a chronic disease requiring ongoing management, even when symptoms are well controlled.

Related Biomarkers

RFRheumatoid Factor CRPC-Reactive Protein ESRErythrocyte Sedimentation Rate ANAAntinuclear Antibodies UAUric Acid

Want your Anti-CCP levels analyzed?

Upload your lab results for an instant AI-powered breakdown of all your biomarkers.

Upload Lab Results →

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reference ranges may vary between laboratories. Always consult your healthcare provider for interpretation of your specific test results.